Ladenburg raised the firm’s price target on United Therapeutics (UTHR) to $344 from $319 and keeps a Buy rating on the shares following the Q3 report. The firm expects the growth of the company’s treprostinil-based products to largely be driven by the growing market potential for Tyvaso. It continues to believe the Tyvaso DPI represents an attractive alternative to the current nebulizer for Tyvaso patients and could be a significant driver for the future expanded uptake of Tyvaso.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $425 from $400 at H.C. Wainwright
- United Therapeutics Reports Strong Q3 2024 Results
- United Therapeutics reports Q3 EPS $6.93, consensus $6.42
- UTHR Earnings this Week: How Will it Perform?
- United Therapeutics price target raised to $400 from $350 at TD Cowen